Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib
| Autor: | Mitchel Williams, Tuhina Govil-Dalela, Ishita Datta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Adolescent Immunology AUTONOMIC INSTABILITY law.invention Bortezomib 03 medical and health sciences 0302 clinical medicine Refractory law Internal medicine medicine Immunology and Allergy Humans Anti-N-Methyl-D-Aspartate Receptor Encephalitis business.industry medicine.disease Intensive care unit 030104 developmental biology Neurology NMDA receptor Rituximab Female Neurology (clinical) business 030217 neurology & neurosurgery Encephalitis Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of neuroimmunology. 355 |
| ISSN: | 1872-8421 |
| Popis: | We report the case of a 14-year-old girl who was diagnosed with N-methyl- d -aspartate (NMDA)-receptor encephalitis, with severe features and autonomic instability, requiring intensive care unit admission. She had poor clinical response to the first-line therapies, she was then started on Rituximab and 6 cycles of Cytoxan infusion. She responded to Bortezomib therapy within 2 weeks of initiation, and with long-term sustenance of improvement in the long-term, also demonstrated by an improvement in NMDA titers . As far as we know, this is the first report of use of Bortezomib therapy in a child with refractory NMDA-receptor encephalitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect